AI Engines For more Details: Perplexity Kagi Labs You
Allergic Conjunctivitis: Levocabastine hydrochloride is specifically indicated for the treatment of allergic conjunctivitis, which is inflammation of the conjunctiva (the clear membrane covering the white part of the eye) due to an allergic reaction. It works by blocking the action of histamine, a chemical released by the immune system during allergic reactions, thereby reducing symptoms such as itching, redness, and discharge from the eyes.
Symptom Relief: Levocabastine hydrochloride provides rapid relief of symptoms associated with allergic conjunctivitis, helping to alleviate discomfort and improve the overall quality of life for individuals affected by this condition.
Topical Application: Levocabastine hydrochloride is typically administered as eye drops for topical application directly onto the surface of the eye. It is generally well-tolerated and can be used as needed to manage acute flare-ups of allergic conjunctivitis.
Minimal Systemic Absorption: Due to its local application, levocabastine hydrochloride has minimal systemic absorption, meaning that it is unlikely to cause significant side effects or interactions with other medications when used as directed.
Duration of Treatment: Levocabastine hydrochloride is intended for short-term use to relieve acute symptoms of allergic conjunctivitis. Prolonged use beyond the recommended duration should be avoided, as it may lead to tolerance or reduced effectiveness over time.
Adverse Effects: While levocabastine hydrochloride is generally well-tolerated, some individuals may experience mild and transient side effects such as temporary stinging or burning sensation upon instillation, blurred vision, or dry eyes. Serious adverse effects are rare but may include allergic reactions or irritation of the eye.
Precautions: Levocabastine hydrochloride should be used with caution in individuals with certain pre-existing eye conditions or hypersensitivity to antihistamines. It is important to follow the prescribing healthcare provider's instructions and to avoid touching the tip of the eye dropper to prevent contamination.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
ADHD | 1.1 | 1.1 | |
Age-Related Macular Degeneration and Glaucoma | 0.3 | -0.3 | |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.4 | |
Allergies | 1.8 | 0.2 | 8 |
Allergy to milk products | 1.1 | 0.7 | 0.57 |
Alopecia (Hair Loss) | 0.7 | 0.7 | |
Alzheimer's disease | 2.3 | 1.4 | 0.64 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.9 | -0.29 |
Ankylosing spondylitis | 2.6 | 0.9 | 1.89 |
Anorexia Nervosa | 0.3 | 0.3 | 0 |
Antiphospholipid syndrome (APS) | 1.3 | 0.4 | 2.25 |
Asthma | 0.1 | 0.2 | -1 |
Atherosclerosis | 0.3 | 0.1 | 2 |
Atrial fibrillation | 0.9 | 1.5 | -0.67 |
Autism | 3.2 | 2.3 | 0.39 |
Barrett esophagus cancer | 0.3 | 0.5 | -0.67 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 1.3 | 1.3 | |
Brain Trauma | 0.2 | -0.2 | |
Carcinoma | 1.8 | 0.5 | 2.6 |
Celiac Disease | 1.5 | 0.9 | 0.67 |
Cerebral Palsy | 0.5 | 0.2 | 1.5 |
Chronic Fatigue Syndrome | 1.8 | 1.8 | 0 |
Chronic Kidney Disease | 1.3 | 1.3 | |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.7 | |
Chronic Urticaria (Hives) | 1.9 | 0.4 | 3.75 |
Coagulation / Micro clot triggering bacteria | 2.1 | 0.5 | 3.2 |
Colorectal Cancer | 4 | 4 | |
Constipation | 0.6 | 0.6 | |
Coronary artery disease | 0.4 | 0.4 | |
COVID-19 | 3.6 | 2.1 | 0.71 |
Crohn's Disease | 4.4 | 1.1 | 3 |
cystic fibrosis | 1.3 | 0.2 | 5.5 |
deep vein thrombosis | 1.3 | 0.5 | 1.6 |
Depression | 3.7 | 2.1 | 0.76 |
Dermatomyositis | 0.5 | 0.5 | |
Eczema | 0.8 | 1.8 | -1.25 |
Endometriosis | 2.3 | 2.3 | |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 1.7 | 1 | 0.7 |
Fibromyalgia | 0.9 | 0.8 | 0.13 |
Functional constipation / chronic idiopathic constipation | 2.2 | 0.7 | 2.14 |
gallstone disease (gsd) | 0.8 | 0.3 | 1.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.5 | 0.2 |
Generalized anxiety disorder | 2 | 0.3 | 5.67 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.5 | -0.5 | |
Graves' disease | 0.5 | 0.5 | |
Halitosis | 0.5 | 0.5 | 0 |
Hashimoto's thyroiditis | 0.2 | 0.6 | -2 |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.1 | 0.2 | 4.5 |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
hyperglycemia | 0.4 | 0.5 | -0.25 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.4 | 1.3 | 0.08 |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 1 | -1 | |
Inflammatory Bowel Disease | 3.5 | 1.4 | 1.5 |
Insomnia | 0.6 | 0.2 | 2 |
Intelligence | 0.5 | 0.1 | 4 |
Intracranial aneurysms | 0.5 | 0.5 | |
Irritable Bowel Syndrome | 1.6 | 0.9 | 0.78 |
Liver Cirrhosis | 2.2 | 1.1 | 1 |
Long COVID | 2.1 | 1.2 | 0.75 |
Lung Cancer | 0.4 | 0.4 | |
ME/CFS with IBS | 0.6 | 0.2 | 2 |
ME/CFS without IBS | 1 | 0.9 | 0.11 |
Metabolic Syndrome | 3.7 | 2.5 | 0.48 |
Mood Disorders | 4.3 | 2.1 | 1.05 |
multiple chemical sensitivity [MCS] | 1.4 | 1.4 | |
Multiple Sclerosis | 2.4 | 2.3 | 0.04 |
Neuropathy (all types) | 0.5 | 0.4 | 0.25 |
neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.2 | 4.5 |
Obesity | 2.2 | 1.9 | 0.16 |
obsessive-compulsive disorder | 3.6 | 0.7 | 4.14 |
Osteoarthritis | 1.5 | 1.5 | |
Osteoporosis | 0.7 | 0.2 | 2.5 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2 | 1.5 | 0.33 |
Polycystic ovary syndrome | 1 | 0.1 | 9 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.1 | |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
primary biliary cholangitis | 0.4 | -0.4 | |
Psoriasis | 1.7 | 1.3 | 0.31 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 0.9 | 2.33 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 1.6 | 0.1 | 15 |
scoliosis | 0.4 | -0.4 | |
Sjögren syndrome | 1.3 | 0.9 | 0.44 |
Sleep Apnea | 0.3 | 0.2 | 0.5 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
Stress / posttraumatic stress disorder | 1.8 | 0.2 | 8 |
Systemic Lupus Erythematosus | 2.8 | 2.8 | |
Tic Disorder | 0.1 | -0.1 | |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 1.3 | 0.5 | 1.6 |
Type 2 Diabetes | 3.7 | 3 | 0.23 |
Ulcerative colitis | 2.1 | 1.5 | 0.4 |
Unhealthy Ageing | 3.5 | 3.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.